Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02916771 · ClinicalTrials.gov registry record · Phase 2
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
A Phase 2 study of Smoldering Multiple Myeloma, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
- 1
- Study location
NCT02916771 is a Phase 2 study of Smoldering Multiple Myeloma that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 61 participants, below the 797-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02916771, a Phase 2 study of Smoldering Multiple Myeloma, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is evaluating a new drug called "ixazomib" as a possible treatment for Smoldering Multiple Myeloma.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Ixazomib
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2016-10 |
| Est. Completion | 2025-01-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02916771
The ClinicalTrials.gov registry entry for NCT02916771 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 797-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (92% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smoldering Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.
NCT02916771 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02916771 about?
NCT02916771 is a clinical study titled "Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma". This research study is evaluating a new drug called "ixazomib" as a possible treatment for Smoldering Multiple Myeloma.
What is the current status of trial NCT02916771?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2016-10. Estimated completion is 2025-01-08.
What conditions does trial NCT02916771 study?
This clinical trial studies the following conditions: Smoldering Multiple Myeloma.
What interventions are being tested in trial NCT02916771?
The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Ixazomib (DRUG).
Who is sponsoring clinical trial NCT02916771?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02916771 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoldering Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
RECRUITING · Phase 2
-
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
RECRUITING · Phase 2
-
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
CAR- PRISM (PRecision Intervention Smoldering Myeloma)
ACTIVE NOT RECRUITING · Phase 2
-
Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.